Half Year 2025 Spirax Group PLC Earnings Call Transcript
Key Points
- Spirax Group PLC (SPXSY) achieved a 3% organic sales growth, outperforming industrial production growth.
- Adjusted operating profit grew by 7% organically, with a group margin increase of 70 basis points to 19.3%.
- Strong demand was observed in biopharm and semiconductor sectors, contributing to double-digit growth in ETS.
- Watson-Marlow's restructuring is on track to deliver annual savings of GBP35 million, supporting future growth investments.
- Cash conversion improved to 61%, reflecting disciplined capital use and investment returns.
- Large project demand from China and Korea faced significant headwinds, impacting overall sales.
- Currency movements negatively impacted sales and operating profit by 3% and 7%, respectively.
- Industrial production growth remains weak in key markets such as Germany, France, Italy, the UK, and the US.
- The macroeconomic environment remains challenging, with uncertainties around tariffs and global trade impacting business confidence.
- Legacy orders in ETS, not repriced for inflation, moderated first-half margins, with clearance expected by the end of 2025.
Hello, and thank you for joining us for our presentation of Spirax Group's half-year results. I'm Nimesh Patel, Group CEO, and I'm joined by Louisa Burdett, Group CFO. As this is an online presentation, please type your questions into the Q&A box on the webcast at any time, and we'll address as many as we can at the end. I'll start by summarizing our performance in the first half.
Against a challenging macroeconomic backdrop, we continue to deliver against our operational priorities by focusing on the controllables, driving group organic sales growth of 3%, ahead of industrial production growth, with adjusted operating profit growing 7% organically. Our group margin was 19.3%, 70 basis points ahead organically as we maintained pricing and cost discipline while also investing in future growth.
The demand trends that I highlighted at the time of our full-year results have continued. In particular, we're seeing strong demand in biopharm and semicon, alongside modest IP growth and weakness in large
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
